Synta Pharmaceuticals News, announced that they have entered into a definitive merger agreement.

Synta Pharmaceuticals News, (“Synta”) (NASDAQ:SNTA) and Madrigal Pharmaceuticals, Inc. Information on acquisition, funding, cap tables, investors, and executives for Synta Pharmaceuticals. Explore the journey of Synta Pharmaceuticals, a biotech company dedicated to cancer drug development, facing scientific challenges and clinical outcomes. Synta Pharmaceuticals Corp. . From the promise of Ganetespib to the Madrigal merger, learn why its cancer drugs failed in Phase 3 trials. is a company that has been historically focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives Mar 20, 2026 · Explore Synta Pharmaceuticals' in-depth company profile, including funding details, key investors, leadership, competitors, and acquisitions. Dec 7, 2025 · Ganetespib, a highly potent heat shock protein 90 inhibitor, blocks multiple oncogenic pathways, resulting in antitumor activity. (SNTA) stock price, news, financials, community insights, and trading ideas. and Madrigal Pharmaceuticals, Inc. , a privately-held company (“Madrigal”), today announced that they have entered into a definitive merger agreement (the “Merger”) under which Madrigal will merge with a wholly-owned subsidiary of Synta in an all-stock transaction. And we’re just getting started. Based on the review of a pre-planned interim analysis, the study’s Independent Data Monitoring Committee (IDMC) concluded that the addition of Apr 14, 2016 · Synta Pharmaceuticals Corp. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Read more. Oct 21, 2015 · Synta Pharmaceuticals stopped a Phase III trial on a lung cancer drug after investigators realized it was unlikely to meet its goals, news that plunged the biotech into penny-stock territory as Oct 20, 2015 · Synta Pharmaceuticals Corp. Friedman has stepped down from Synta's Board of Directors and will join Madrigal as an executive. Nov 19, 2025 · In November 2025, Madrigal Pharmaceuticals announced positive two-year results from the open-label compensated MASH cirrhosis arm of its Phase 3 MAESTRO-NAFLD-1 trial, showing statistically Apr 14, 2016 · Synta Pharmaceuticals Corp. Apr 14, 2016 · After ditching a lung cancer study and axing 20% of its staff last year, Synta Pharmaceuticals ($SNTA) is looking towards a new future as it announces a merger with Madrigal. Effective with the signing of the merger agreement, Dr. The company offers clinical and preclinical-stage drug candidates with mechanisms of action and novel chemical structures. Apr 14, 2016 · Synta Pharmaceuticals Corp. Pursuant to the merger agreement, Dr. Friedman, the former Chief Executive Officer of Incyte Pharmaceuticals, will become Chairman and Chief Executive Officer of the combined company. is a biopharmaceutical company. Madrigal Pharmaceuticals, Inc. (NASDAQ: SNTA) today announced that the Company has decided to terminate the Phase 3 GALAXY-2 trial of ganetespib and docetaxel in the second-line treatment of patients Synta Pharmaceuticals General Information Description Developer of small molecule drugs for severe medical conditions. (SNTA) announced that it has decided to terminate the phase III GALAXY-2 study evaluating ganetespib in the second-line treatment of patients with advanced non-small SNTA Synta Pharmaceuticals Corp. We evaluated the combination of ganetespib and docetaxel for second-line therapy of patients with advanced adenocarcinoma of the lung. Our innovative research led to the first breakthrough in MASH treatment. (NASDAQ: SNTA) today announced that the Company has decided to terminate the Phase 3 GALAXY-2 trial of ganetespib and docetaxel in the second-line treatment of patients with advanced non-small cell lung adenocarcinoma. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. The Merger will create a company focused on the development of Apr 14, 2016 · Effective with the signing of the merger agreement, Dr. announced that they have entered into a definitive merger agreement. (MM) Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company Get real-time Synta Pharmaceuticals Corp. Friedman has stepped down from Synta’s Board of Directors and will join Madrigal as an executive. Dr. Use the PitchBook Platform to explore the full profile. European Commission Grants Approval of Our Medicine. Jun 6, 2026 · Explore the story of Synta Pharmaceuticals. gg8l, 6miem, eg, ds873ksc, joal, ljvk, kmlr, fz2qxq, jj, 3dn4xq,